Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. The company's product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial that is used for the treatment of ADHD. It also develops SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression. The company markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:SUPN
CUSIP86845910
Phone301-838-2500
Debt
Debt-to-Equity Ratio0.82
Current Ratio2.74
Quick Ratio2.54
Price-To-Earnings
Trailing P/E Ratio35.56
Forward P/E Ratio23.46
P/E GrowthN/A
Sales & Book Value
Annual Sales$302.24 million
Price / Sales7.74
Cash Flow$1.4124 per share
Price / Cash31.72
Book Value$5.22 per share
Price / Book8.58
Profitability
EPS (Most Recent Fiscal Year)$1.26
Net Income$57.28 million
Net Margins24.17%
Return on Equity30.57%
Return on Assets15.50%
Miscellaneous
Employees422
Outstanding Shares52,210,000
Market Cap$2.41 billion
Supernus Pharmaceuticals (NASDAQ:SUPN) Frequently Asked Questions
What is Supernus Pharmaceuticals' stock symbol?
Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."
How were Supernus Pharmaceuticals' earnings last quarter?
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) issued its earnings results on Tuesday, August, 7th. The specialty pharmaceutical company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.43 by $0.14. The specialty pharmaceutical company earned $99.54 million during the quarter, compared to analysts' expectations of $101.01 million. Supernus Pharmaceuticals had a return on equity of 30.57% and a net margin of 24.17%. View Supernus Pharmaceuticals' Earnings History.
When is Supernus Pharmaceuticals' next earnings date?
What price target have analysts set for SUPN?
10 brokers have issued 1 year price objectives for Supernus Pharmaceuticals' shares. Their predictions range from $44.00 to $66.00. On average, they anticipate Supernus Pharmaceuticals' share price to reach $54.90 in the next year. This suggests a possible upside of 22.5% from the stock's current price. View Analyst Price Targets for Supernus Pharmaceuticals.
What is the consensus analysts' recommendation for Supernus Pharmaceuticals?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Supernus Pharmaceuticals.
What are Wall Street analysts saying about Supernus Pharmaceuticals stock?
Here are some recent quotes from research analysts about Supernus Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. " (8/1/2018)
- 2. FBR & Co analysts commented, "We are initiating coverage of Supernus Pharmaceuticals (SUPN) with a Buy rating and a 12-month price target of $53 per share. We see strong revenue growth exceeding 25% per year for 2017–2019 with in-line drugs Trokendi XR (epilepsy/ migraine) and Oxtellar XR (epilepsy) driving growth. Starting in 2020, we expect contribution from late-stage pipeline drugs SPN-812, which is a non-stimulant ADHD drug, and SPN-810 for impulsive aggression. We model EPS at $1.05 in 2017, $1.70 in 2018, and $2.35 in 2019 including a full tax rate. Our 2017 EPS estimate compares unfavorably to 2016, which included a tax benefit of $40.8 million or ~$0.80 per share. Our price target averages our DCF valuation and a P/E-derived target, which is 35x 2018E EPS of $1.70 discounted to present at 10%. At current prices, the shares have corrected by ~18% from all-time highs after an update on pipeline drug SPN-810 raised risks on timing/approvability. We see this drop as an opportunity to establish positions." (10/19/2017)
- 3. Cantor Fitzgerald analysts commented, "Interim look at SPN-810 Phase 3 program leads to elimination of the low dose. SUPN announced that an interim analysis of the ongoing Phase 3 trials (CHIME 1 and CHIME 2) in impulsive aggression (IA) resulted in the decision to discontinue the low dose arm, 18mg daily, and randomization of future clinical trial subjects to receive either placebo or 36mg per day." (9/19/2017)
Who are some of Supernus Pharmaceuticals' key competitors?
Some companies that are related to Supernus Pharmaceuticals include Perrigo (PRGO), Beigene (BGNE), Sarepta Therapeutics (SRPT), Valeant Pharmaceuticals (VRX), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Alkermes (ALKS), Ionis Pharmaceuticals (IONS), GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR), Catalent (CTLT), Dr.Reddy's Laboratories (RDY), Ligand Pharmaceuticals (LGND), FibroGen (FGEN) and Loxo Oncology (LOXO).
Who are Supernus Pharmaceuticals' key executives?
Supernus Pharmaceuticals' management team includes the folowing people:
- Mr. Jack A. Khattar, Founder, Pres, CEO, Sec. & Director (Age 57)
- Mr. Gregory S. Patrick, VP & CFO (Age 67)
- Dr. Padmanabh P. Bhatt, Chief Scientific Officer and Sr. VP of Intellectual Property (Age 61)
- Dr. Stefan K. F. Schwabe, Chief Medical Officer and Exec. VP of R&D (Age 66)
- Dr. Todd Horich, VP of Marketing
Has Supernus Pharmaceuticals been receiving favorable news coverage?
News headlines about SUPN stock have trended somewhat positive this week, according to Accern Sentiment. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Supernus Pharmaceuticals earned a news impact score of 0.22 on Accern's scale. They also assigned news coverage about the specialty pharmaceutical company an impact score of 49.31 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days. View Recent Headlines for Supernus Pharmaceuticals.
Who are Supernus Pharmaceuticals' major shareholders?
Supernus Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.85%), Bank of New York Mellon Corp (2.79%), Dimensional Fund Advisors LP (2.61%), Acadian Asset Management LLC (2.17%), Wells Fargo & Company MN (1.85%) and FMR LLC (1.82%). Company insiders that own Supernus Pharmaceuticals stock include Gregory S Patrick, Padmanabh P Bhatt, Stefan KF Schwabe and Victor Vaughn. View Institutional Ownership Trends for Supernus Pharmaceuticals.
Which major investors are selling Supernus Pharmaceuticals stock?
SUPN stock was sold by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS, Russell Investments Group Ltd., Rice Hall James & Associates LLC, Millennium Management LLC, Rothschild Asset Management Inc., Ashford Capital Management Inc., Algert Global LLC and Northpointe Capital LLC. Company insiders that have sold Supernus Pharmaceuticals company stock in the last year include Gregory S Patrick, Padmanabh P Bhatt, Stefan KF Schwabe and Victor Vaughn. View Insider Buying and Selling for Supernus Pharmaceuticals.
Which major investors are buying Supernus Pharmaceuticals stock?
SUPN stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, BlackRock Inc., Renaissance Technologies LLC, Voya Investment Management LLC, Scout Investments Inc., Castleark Management LLC, Carillon Tower Advisers Inc. and Bank of America Corp DE. View Insider Buying and Selling for Supernus Pharmaceuticals.
How do I buy shares of Supernus Pharmaceuticals?
Shares of SUPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Supernus Pharmaceuticals' stock price today?
One share of SUPN stock can currently be purchased for approximately $44.80.
How big of a company is Supernus Pharmaceuticals?
Supernus Pharmaceuticals has a market capitalization of $2.41 billion and generates $302.24 million in revenue each year. The specialty pharmaceutical company earns $57.28 million in net income (profit) each year or $1.26 on an earnings per share basis. Supernus Pharmaceuticals employs 422 workers across the globe.
How can I contact Supernus Pharmaceuticals?
Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The specialty pharmaceutical company can be reached via phone at 301-838-2500 or via email at [email protected]
MarketBeat Community Rating for Supernus Pharmaceuticals (NASDAQ SUPN)
MarketBeat's community ratings are surveys of what our community members think about Supernus Pharmaceuticals and other stocks. Vote "Outperform" if you believe SUPN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SUPN will underperform the S&P 500 over the long term. You may vote once every thirty days.
